Lupus: Peptide P140/LupuzorTM effectiveness confirmed

A clinical trial with 149 patients suffering from the very disabling autoimmune disease systemic lupus erythematosus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France.

The peptide, known as P140/LupuzorTM, is well tolerated by patients and leads to regression of the disease.

Under the CNRS patent, ImmuPharma-France, which funded the trial, has an exclusive license to use the peptide.

Now the final phase of clinical tests should soon confirm these results and contribute to the development of a drug without the side effects of existing treatments, which use cortico-steroids and immunosuppressants.

These results are published online in the .


Explore further

Small peptide ameliorates autoimmune skin blistering disease in mice

More information: Zimmer R., Scherbarth H.R., Rillo O.L., Gomez-Reino J. and Muller S. Annals of Rheumatic Diseases (doi: 10.1136/annrheumdis-2012-202460)
Provided by CNRS
Citation: Lupus: Peptide P140/LupuzorTM effectiveness confirmed (2013, January 25) retrieved 22 November 2019 from https://medicalxpress.com/news/2013-01-lupus-peptide-p140lupuzortm-effectiveness.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments